Sino Biological recombinant allergen proteins are core reagents for allergen detection

« Previous article
Salmonella Scare Cau...

11th November 2019  Author: Paul Carton

Mark Bamforth’s New $82m Microbiome Venture with ThermoFisher 

A recently formed microbiome contract development and manufacturing organization (CDMO) have secured $82 million in funding through a single private equity firm and has also established a strategic partnership with ThermoFisher.

Arranta Bio (“Arranta”), will provide live biopharmaceutical products (LBP) to the microbiome therapeutics market. Services provided by Arranta will be bacterial fermentation, isolation, drying, and encapsulation to clients that are designing biopharmaceuticals to target the microbiome, ‘the second genome.’

Former Brammer Bio CEO Mark Bamforth set up Arranta in May of this year, with Ian Baird. Mark’s last two ventures Brammer Bio and Gallus Biopharmaceuticals, were both acquired by ThermoFisher, the former, a viral vector CDMO was bought for $1.7billion.

As part of the strategic partnership with ThermoFisher, Arranta will now provide materials for gene therapy production with Arranta having full access to ThermoFisher’s products and services.



Date Published: 11th November 2019

Source article link: View

View full company details